

GAVI 6.0 – THE ALLIANCE'S STRATEGY 2026-2030

BOARD MEETING
Johannes Ahrendts
6-7 June 2024, Geneva, Switzerland

gavi.org



The design of Gavi 6.0 has followed three phases led by the Board and informed by extensive country-centric consultations



Gavi 6.0 strategy one-pager (2026 – 2030)

VISION

Leaving none behind with immunisation



MISSION

VACCINES

IMMUNISATION PROGRAMS

VACCINES AND RELATED PRODUCTS

PRINCIPLES

To **save lives** and **protect people's health**
by increasing **equitable and sustainable use of vaccines**

GOALS

- Zero-dose and missed communities, first priority
- Gender-focused
- Differentiated, fragility-responsive
- Climate-sensitive
- Innovative
- Collaborative, accountable

ENABLERS

- Epidemics, and pandemic-prone diseases
- New disease introductions
- Climate change and extreme weather events
- Antimicrobial resistance
- Global political commitment
- Collaboration with private sector and development finance institutions

Five work areas to operationalise Gavi 6.0 | High-level approach 2024-2025

Finalise sub-strategies

1 Development of Gavi 6.0 **theory of change** and **measurement framework**

- 2 Finalisation of key **sub-strategies**, to include:
- Health Systems Strategy
 - Approach to Fragile, Conflict & Humanitarian settings
 - Climate Change approach

Hardwire in policies

3 Updates of Gavi's **programmatic policies** (Funding Policy Review)

Evolve the Alliance & Secretariat model

- 4 Evolution of the Alliance **partnership approach**, including to
- Enable Partners' Engagement Framework (PEF) for new partnership agenda, including resource allocation
 - Set-up new local and regional partnerships
 - Drive collaboration with other global initiatives
- 5 Update of Secretariat **operating model** (including through **operational excellence** agenda, including
- Funding guidelines
 - Grant management processes (EVOLVE), including funding lever consolidation
 - Optimise internal resource allocation (organisational improvements)
 - Business partnering in programmes team

Close interlinkages with replenishment outcomes and detailed Gavi 6.0 financial forecasting

Gavi 6.0 costing – Key underlying assumptions

Key Headlines - AFC Strategic
Costing Review - 30 May 2024

Key drivers of costs

+10% increase in vaccinated infants

Across Gavi-supported countries: **+10% growth in vaccinated infants:**

- **+5%** increase in birth cohort
- **+5%** increase in coverage

Increased breath of protection

Rollout and scale up of new vaccines including:

- Malaria
- Multivalent Meningococcal Conjugate Vaccine (MMCV)
- Hexavalent
- Cholera

+11% inflation eroding spending power of Gavi's investments

- US Inflation Forecast:
 - 2021-2025: 24%
 - 2026-2030: 11%
- While Gavi disburses in US\$, impact of inflation likely to be higher in specific countries

Key Gavi model efficiencies

Market shaping

- **Weighted average price reduced by -6%** versus inflation
- **40% price reductions** on newly launched vaccines
- **9 new reductions** on lowest price per presentation allowing for **switches to lower price products**

Country co-financing


Continued increase in country co-financing of vaccines up to **US\$ 1.7-1.9 billion**, representing an **increase of 30-50%** versus Gavi 5.0/5.1 under the enhanced model

More efficient Alliance and operating model

- ~US\$ 0.7 billion potential efficiencies targeted in cash-based programmes, PEF TA, Secretariat and other envelopes, implying lower overall share of cash and PEF support versus Gavi 5.0/5.1
- Noting increasing complexity in implementing countries, e.g. increased fragility & conflict will require careful management

Gavi 6.0 costing – Strategic Cost Estimate of US\$ 11.9 billion

Gavi expenditure overview



Overview: ~US\$ 11.9 billion

- **US\$ 6.6 billion for vaccine procurement** reflecting increased children (population & coverage) & support for new vaccines
- **US\$ 1.6 billion for HSIS**, flat versus Gavi 5.1, and 15% lower than Gavi 5.0 base
- **US\$ 1 billion** for Vaccine Introduction Grant (VIGS)/Ops/Switch grants to fund (particularly) increasing campaigns
- **US\$ 0.9 billion for PEF TA** and **US\$ 0.2 billion for 'other PEF'** including procurement fees
- **US\$ 0.25-0.45 billion** for the enhanced ELTRACO model (mid-point used in the graph) and **US\$ 0.25 billion for the Catalytic phase** included in the 'special envelope'
- **US\$ 0.8 billion for Secretariat & PEF Opex**


¹ HSIS (ex-Ops/VIGs) includes Health Systems Strengthening, Equity Accelerator Funding (EAF) and Cold Chain Equipment Optimisation Platform (CCEOP)

² PEF includes Targeted Country Assistance (TCA), Strategic Focus Areas (SFA), Foundational Support (FS) as well as Procurement Fees, Partnerships in Innovation and post-transition support (Gavi 5.1 only)

³ Special envelopes / other includes Middle-Income Country support strategy and costs associated with Eligibility, Co-Financing and Transition as well as Financial Management and Fiduciary Risk Assurance, COVID-19 vaccine delivery costs, Vaccine Innovation Prioritisation Strategy (VIPS) and the Coalition for Epidemic Preparedness Innovations (CEPI)

⁴ Opex includes Secretariat costs and PEF studies and evaluations | ⁵ US\$ 11.9 billion is net of US\$ 100 million additional efficiencies across partner cost and Opex (to be allocated)

Overview of Gavi's potential resources as at the end of 2025



- 1 The Board has approved AVMA, Day Zero Financing Facility, Big Catch-Up programmes. Donor **repurposing in progress** ahead of announcements in June. Note some spend in 5.1, 6.0, 7.0, 8.0.
- 2 Programmatic funding carry over from **Gavi 5.1 AND World Bank IFFIm** forecast for Gavi 6.0 (5.1 both numbers as per May 2024 AFC forecast). World Bank have updated IFFIm forecast from US\$ 350 to US\$ 655 million. Investment income forecast as per new methodology
- 3 US \$1.8 billion COVAX AMC funds as May 2024 AFC. Evaluation will allow donors to discuss the future of the instrument. **Donor consultations ongoing to potentially transfer or use funds for 6.0 activities**, with potential earmarking for some donors.
- 4 'Funding 'Risk and Ops' .Opportunities are all future receipts (not cash in bank), **all are uncertain, currently COVAX earmarked and pending final decisions on use of funds.**
- 5 ***Most significant uncertainty remains repurposing of COVAX AMC funds***

'Funding' Risks and Opportunities NOT in forecast due to uncertainty (including repurposing)

Opportunities for COVAX AMC, AVMA and DZF

Risk

1. Future COVAX AMC interest (2024-25)	Market risk; donor decision use of funds	US\$ 0-180m	●
2. Future AVMA / DZF interest (2024-25)	Market risk; donor decision use of funds	US\$ 0-88m	●
3. Outstanding COVAX Donor pledges	Donor decision on pledges	US\$ 0-129m	●
4. Future Manufacturer/NFC receipts (2024-28)	Manufacturer unable to pay; donor use of funds	US\$ 0-400m	●
5. Lower COVID-19 programme spend (2024-25)	Lower demand for programme; donor use of funds	US\$ 0-100m	●
6. Holistic treasury investment review (2026-30)	Lower investment returns; donor use of funds	US\$ 0-373m	●

Level of certainty: HIGH ● MEDIUM ● LOW ● Overall risk is combination of risk of not materialising x risk of not being repurposed

Assumption: No change in Programme Funding Policy Cash/Investment reserve requirements (9 months), est US\$ 1,56 billion.

Action Requested of the Board

The Gavi Alliance Board is requested to approve the framework for the Alliance strategy 2026-2030 ('strategy one-pager') attached as Annex A to Doc 05.

Thank you